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Recently, an inverse relationship between resistance to platinum-based chemotherapeutic agents and taxanes has been
implicated in breast and ovarian cancers, and a possible pivotal role for BRCA1 has also been suggested. Because cis-
diamminedichloroplatinum (CDDP) and taxanes are the most active antitumor agents against head and neck squamous cell
carcinoma(HNSCC),weanalyzedthesensitivityofnineHNSCCcelllinesandtheirpreviouslyestablishedderivedCDDP-resistant
cell lines to two representative taxanes: docetaxel and paclitaxel. None of the nine original cell lines showed any cross resistance
betweenCDDPandtaxanes,butoneoftheCDDP-resistantcelllines,RPMI2650CR,demonstratedhypersensitivitytobothtaxanes
when compared to the parental cell line, RPMI2650. Furthermore, RPMI2650CR exhibited increased expression of BRCA1. These
data suggest that (i) taxanes are a good candidate for a second-line therapeutic drug for HNSCC patients with acquired CDDP
resistance and (ii) BRCA1 can be a candidate marker for predicting an inverse CDDP/taxane sensitivity phenotype in HNSCC.
1.Introduction
Cisplatin (cis-diamminedichloroplatinum, CDDP), a DNA
damaging drug, is the most active antitumor agent for
treating patients with head and neck squamous cell carci-
noma (HNSCC). However, acquired resistance to CDDP is
one of the major problems in the clinical management of
such patients [1]. CDDP-resistance has been reported to be
associated with decreased cellular accumulation of the drug,
increased levels of glutathione, DNA repair, and antiapop-
totic activity [2] .H e n c ew ef o c u s e do nf a c t o r so rm o l e c u l e s
that are closely associated with sensitivity and/or resistance
to CDDP, and we identiﬁed IGF2 as one of the candidate
molecules for acquired CDDP resistance [3]. Ultimately,
we need to ﬁnd a way to deduce the molecular mechanisms
for acquisition of resistance. In the meantime, it is also
very important to ﬁnd alternative drug(s) or method(s) for
defeating the acquired resistance. Stordal et al. highlighted
an inverse relationship between CDDP and taxane resistance
[4]. These drugs function in diﬀerent phases of the cell
cycle; thus CDDP and taxanes are often applied as combined
chemotherapy [5, 6]. Herein, we studied the inverse relation-
ships of resistance between CDDP and taxanes in HNSCC
celllinesandobservedthatoneofourcelllineswithacquired
CDDP resistance showed increased taxane sensitivity when
compared with its parental cell line. Furthermore, dramatic
upregulation of BRCA1 was also observed in these CDDP-
resistant cells. Although our ﬁndings are just the tip of
the iceberg and many other mechanisms are yet-to-be-
discovered, it is possible that the BRCA1 status can be used2 International Journal of Otolaryngology
as one of the biomarkers to forejudge the taxane sensitivity
of HNSCC with acquired CDDP resistance.
2.MaterialsandMethods
2.1. Cell Lines. Nine human HNSCC cell lines were used;
the origins of the cell lines are one nasal cavity cancer
(RPMI2650), two maxillary cancers (HSQ89, IMC4), and six
oral-cavity cancers (HSC2, HSC3, HSC4, Ca9-22, HO-1-u-
1, SAS). These cells were grown by methods indicated by the
original developers. We also established their derived CDDP-
resistant (CR) cell lines by a method described elsewhere [7].
2.2. MTT Assay. At o t a lo f5× 103 cells/well was seeded in
each well of ﬂat-bottomed 96-well plates in triplicate and
cultured in 200μL of medium. After 18 hours of incubation,
either CDDP, or paclitaxel or docetaxel were added to the
media using a ﬁvefold dilution series, and the cells were
cultured for 48 hours. Then the medium was replaced with
100μL of 0.05% 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-
tetrazo-lium bromide (MTT)/PBS and incubated for one
hour. After the incubation, the MTT solution was removed,
and the cells were suspended in 100% ethanol. Absorption
was measured at 590nm using a Versamax microplate reader
(Amersham Biosciences Corp., Piscataway, NJ). Independent
triplicate assays were performed. All values represent the
mean ± standard deviation (SD) from 3 sets of independent
cultures.
2.3. Western Blotting Analysis for BRCA1. At o t a lo f2× 105
cells were harvested, and protein concentrations in total cell
lysates were measured using a DC protein assay kit (Bio-Rad,
Hercules, CA). A 40μg aliquot of the protein was subjected
to immunoblotting using a 10–20% polyacrylamide gradient
gel (Bio-Rad, Hercules, CA). Antibodies used were rabbit
anti-BRCA1monoclonalantibody(Oncogene,Boston,MA),
mouse anti-β actin monoclonal antibody (Sigma, St Louis,
MO), and horseradish peroxidase conjugated anti-mouse
immunoglobulin antibodies (Amersham Biosciences Corp.,
Piscataway, NJ). For blocking conditions and concentrations
of antibodies, we followed the manufacturer’s recommenda-
tions.SignalswerevisualizedbyreactionwithECLDetection
Reagent (Amersham Biosciences Corp., Piscataway, NJ) and
digitallyprocessedusingLAS1000PluswithaScienceLab99
Image Gauge (Fuji Photo Film, Minamiashigara, Japan).
2.4. Statistical Analysis. The statistical diﬀerences in cell
viability between the parental and CDDP-resistant cell lines
were determined with student’s t-test, and the signiﬁcant
diﬀerence level was established at P<0.05.
3. Results andDiscussion
In a previous study, we successfully established CDDP resis-
tant cell lines from all of the HNSCC cell lines we attempted
[3]. These results may indicate that acquisition of CDDP
c h e m o r e s i s t a n c ei sn o tar a r ee v e n t ;w ef r e q u e n t l yo b s e r v e
such acquired resistance in HNSCC patients undergoing
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Figure 1: Cell viability with chemotherapeutic agents was assessed
by MTT assay. RPMI2650CR shows higher resistance to cisplatin
that the parental RPMI2650 (a) but has higher sensitivities to both
docetaxel (b) and paclitaxel (c).International Journal of Otolaryngology 3
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Figure 2: Western blot analysis of BRCA1 in HNSCC cell lines and their derived CDDP-resistant (CR) cell lines. Marked upregulation of
BRCA1 (220kDa) was observed only in the RPMI2650CR cell line. Beta actin (ACTB) was used as an internal control.
chemotherapy in the clinical setting. Hence it is important to
understand the mechanisms of acquired resistance to CDDP,
as well as trying to ﬁnd alternative methods for clinical
management of patients with acquired CDDP resistance.
We also identiﬁed IGF2 as one of the candidate genes for
acquired CDDP resistance in HNSCC by cDNA microarray
analysis, and the stably IGF2-expressing RPMI2650 cells
did show resistance to CDDP similar to that observed in
RPMI2650CR [3].
Stordal et al. reported an inverse correlation of chemo-
sensitivity between taxane and CDDP [4]. Therefore, we fur-
ther performed an MTT assay to elucidate taxane sensitivity
using our established acquired CDDP-resistant HNSCC cell
lines; 8 of the 9 analyzed CDDP-resistant cell lines showed
sensitivities similar to their parental cell lines (data not
shown), but the RPMI2650-derived CDDP-resistant cell line
(RPMI2650CR) demonstrated hypersensitivity to taxanes
when compared to the parental cell line (see Figure 1). It
is notable that the IC50 value changed by one order of
magnitude for CDDP chemosensitivity, but the IC50 values
diﬀered by two orders of magnitude in chemosensitivities
to both taxanes. These phenomena were reproducible for
the two diﬀerent taxanes. Stably IGF2-expressing RPMI2650
was also used to determine the taxane sensitivity, but it
showed a sensitivity similar to that of parental RPMI to both
taxanes (data not shown), indicating that IGF2 is not
involved in the hypersensitivity to taxanes. Although the
molecular mechanisms behind the inverse correlation of
chemosensitivity between taxane and CDDP are not well
understood, it can be proposed that taxanes are good candi-
dates as a second-line chemotherapeutic choice for HNSCC
patients with acquired chemoresistance to CDDP.
Several studies have suggested an association between
taxanesensitivityandBRCA1expression[8],sowethenana-
lyzed BRCA1 expression by Western blotting analysis in the
9 acquired CDDP-resistant cell lines we established. Results
are shown in Figure 2; prominent upregulation of BRCA1
was observed in RPMI2650CR, and none other cell lines
demonstrated a similar pattern. The possible clinical signif-
icance of BRCA1 detection is that preoperative immunos-
taining of a biopsy specimen for BRCA1 may indicate the
eﬀectiveness of chemotherapy with taxanes and may possibly
additionally estimate CDDP sensitivity, ultimately leading
to avoidance of the unnecessary employment of rich CDDP
treatment, which has adverse side eﬀects. Further studies are
necessary to conﬁrm the association of BRCA1 expression
with chemotherapy resistance in HNSCC.
4. Conclusions
Acquired CDDP resistance is often observed in patients
with HNSCC, and taxanes are used as the second-line
chemotherapeutic drug for HNSCC. We observed that an4 International Journal of Otolaryngology
acquired CDDP-resistant HNSCC cell line showed higher
sensitivity to taxane by two orders of magnitude than its
parental cell line. Prominent upregulation of BRCA1 was
also observed in this CDDP-resistant/taxane-sensitive cell
line. Expression status of BRCA1 can be a biomarker to
forejudge the taxane sensitivity to patients with acquired
CDDP-resistant HNSCC.
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